What type of study is this?

September 10, 2025Virchows ArchivOpen Access

Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring

View Full Paper

Ask AI

Bookmark

Claudin-18.2 is expressed at a high rate in pancreatic ductal adenocarcinoma, indicating its potential as a biomarker.
Current clinical trials are exploring anti-CLDN18.2 targeted therapies for patients with advanced pancreatic cancer.
Standardization of claudin-18 testing will enhance interpretation and guide patient selection for targeted therapies.
There are specific pitfalls in claudin-18 staining interpretation that must be addressed to improve diagnostic accuracy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This review outlines claudin-18 immunohistochemical evaluation in pancreatic cancer, suggesting standardized testing practices for better clinical outcomes.

Cite This Study

Luchini et al. (2025) studied this question.

synapsesocial.com/papers/68c1ce6754b1d3bfb60f57c2 https://doi.org/10.1007/s00428-025-04222-2

View Full Paper

Ask AI

Bookmark

Implication

This review outlines claudin-18 immunohistochemical evaluation in pancreatic cancer, suggesting standardized testing practices for better clinical outcomes.

Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring

Key Points

Discussion

Implication

Cite This Study

Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider